Weiji Weng1, Xu Chen2, Shaohui Gong2, Liemei Guo1, Xiaohua Zhang1. 1. a Department of Neurosurgery, Renji Hospital , Shanghai Jiao Tong University School of Medicine , Shanghai , China. 2. b Department of Neurosurgery , Shangrao People's Hospital , Shangrao , China.
Abstract
BACKGROUND: Neutrophil-lymphocyte ratio (NLR) is a simple, low-cost and easily measured inflammation marker, corresponding with pathological tumor grading and clinical prognosis in various cancers. OBJECTIVES: This study aimed to investigate the relationship between preoperative NLR and glioma grading and also the correlation between NLR and glioblastoma survival. METHODS: The preoperative NLR was analyzed retrospectively in 239 gliomas of different grades, and receiver operating characteristic (ROC) curve analysis was adopted to investigate the prediction of glioma grading. Univariate and multivariate analyses were performed to analyze the variables of overall survival (OS) of glioblastoma patients. RESULTS: There were significant differences in the preoperative NLR values among the four glioma groups, with the highest values observed in the glioblastoma group (p < 0.05). ROC curve analysis showed the NLR value of 2.36 was a cutoff point for predicting glioblastoma. The OS of patients with high NLR (≥ 4.0) was shorter compared with that with low NLR (< 4.0) (mean 11.23 vs. 18.56 months, p < 0.05). Univariate analysis and multivariate analysis indicated age≥ 60, NLR≥ 4.0, Karnofsky Performance Scores (KPS) ≤ 70, incomplete tumor resection, incomplete Stupp protocol accomplishment and the isocitrate dehydrogenase 1 (IDH1) wild-type as independent prognostic indicators for poor outcome (each p < 0.05). CONCLUSION: The preoperative NLR was correlated with glioma grading, and the elevated NLR was an independent predictive factor for poor outcome of glioblastoma patients. Abbreviation IDH1: Isocitrate dehydrogenase 1IL-8: Interleukin-8KPS: Karnofsky Performance ScoresNLR: Neutrophil-lymphocyte ratioOS: Overall survivalROC: Receiver operating characteristicSD: Standard deviationsWHO: World Health Organization.
BACKGROUND: Neutrophil-lymphocyte ratio (NLR) is a simple, low-cost and easily measured inflammation marker, corresponding with pathological tumor grading and clinical prognosis in various cancers. OBJECTIVES: This study aimed to investigate the relationship between preoperative NLR and glioma grading and also the correlation between NLR and glioblastoma survival. METHODS: The preoperative NLR was analyzed retrospectively in 239 gliomas of different grades, and receiver operating characteristic (ROC) curve analysis was adopted to investigate the prediction of glioma grading. Univariate and multivariate analyses were performed to analyze the variables of overall survival (OS) of glioblastomapatients. RESULTS: There were significant differences in the preoperative NLR values among the four glioma groups, with the highest values observed in the glioblastoma group (p < 0.05). ROC curve analysis showed the NLR value of 2.36 was a cutoff point for predicting glioblastoma. The OS of patients with high NLR (≥ 4.0) was shorter compared with that with low NLR (< 4.0) (mean 11.23 vs. 18.56 months, p < 0.05). Univariate analysis and multivariate analysis indicated age≥ 60, NLR≥ 4.0, Karnofsky Performance Scores (KPS) ≤ 70, incomplete tumor resection, incomplete Stupp protocol accomplishment and the isocitrate dehydrogenase 1 (IDH1) wild-type as independent prognostic indicators for poor outcome (each p < 0.05). CONCLUSION: The preoperative NLR was correlated with glioma grading, and the elevated NLR was an independent predictive factor for poor outcome of glioblastomapatients. Abbreviation IDH1: Isocitrate dehydrogenase 1IL-8: Interleukin-8KPS: Karnofsky Performance ScoresNLR: Neutrophil-lymphocyte ratioOS: Overall survivalROC: Receiver operating characteristicSD: Standard deviationsWHO: World Health Organization.
Authors: Artur Nóbrega Lima Rodrigues de Morais; Victor Matheus Ribeiro Baylão; Tamires Martins Silva; Alexandra Gomes Dos Santos; Mayara Azevedo; Adilson J M de Oliveira Journal: Neurosurg Rev Date: 2021-02-15 Impact factor: 3.042
Authors: George S Stoyanov; Emran Lyutfi; Reneta Georgieva; Deyan L Dzhenkov; Lilyana Petkova; Borislav D Ivanov; Ara Kaprelyan; Peter Ghenev Journal: Cureus Date: 2022-06-09
Authors: Pawel Jarmuzek; Marcin Kot; Piotr Defort; Jakub Stawicki; Julia Komorzycka; Karol Nowak; Anna Tylutka; Agnieszka Zembron-Lacny Journal: J Clin Med Date: 2022-06-13 Impact factor: 4.964
Authors: Hamza Ali; Romée Harting; Ralph de Vries; Meedie Ali; Thomas Wurdinger; Myron G Best Journal: Front Oncol Date: 2021-06-04 Impact factor: 6.244